Pain-Identifying and Commercializing First-in-Class Innovati

1. Frontier Pharma: Pain-Identifying and Commercializing First-in-Class Innovation

2. Report Description Large and Innovative Pipeline The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research’s analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation. This is in stark contrast to the pain therapeutics market, which has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and the concomitant mechanisms of action. Moderate-to-severe pain continues to be dominated by opioids that are increasingly being reformulated to offer abuse-resistance, while mild pain is effectively treated with Non-Steroidal Anti-Inflammatory Drugs (NSAID). However, significant unmet needs remain, as chronic pain and some neuropathic pain subtypes do not respond well to existing therapies, which are not adequate to treat associated hypersensitization and do not align to the underlying molecular pathophysiological profile.

3. Report Description • Despite being mostly distributed in the early stages of development, first-in-class innovation is particularly concentrated on novel molecular targets that are aligned to the central sensitization associated with neuropathic pain, which is arguably the most debilitating and difficult-to-treat type of chronic pain. This gives them the potential to transform the future market by expanding the range of drug classes. • Highly Diversified Range of Innovative Programs in Early Pipeline and in Granted Patents • Get more about this report at: http://www.bigmarketresearch.com/frontier-pharma-pain-identifying-and-commercializing-first-in-class-innovation-market

4. Report Description • Pain is a complex and multifaceted disorder with a complex interplay between different pathological processes, and different pain subtypes exhibit distinct underlying etiologies and pathophysiologies. While technological advances and extensive research efforts have furthered the understanding of these complex underpinnings, gaps remain. However, these insights have translated into the expanding pool of novel therapeutic targets, as reflected by the highly innovative pipeline. GBI Research’s proprietary analysis shows that early-stage, first-in-class programs exhibit a higher level of diversity with respect to novel therapeutic targets. • The significant diversity in terms of targets is a reflection of the complex underpinnings of distinct pain subtypes. Although the pipeline continues to feature established therapies, the range of mechanisms of action employed by novel compounds is extremely diverse, with the vast majority residing in the Preclinical stage. This innovation and diversity is maintained throughout the pipeline from early- to late-stage development, although the degree of innovation diminishes from Phase II. Additionally, although NSAIDs and opioids remain the cornerstone of pain treatment, GBI Research analysis indicates a shift towards pain subtypes that are more difficult to treat.

5. Report Description In addition, GBI Research’s comprehensive and complementary analysis of granted patents highlighted a significant number of first-in-class product technologies, many of which have not been identified in the pain product pipelines or even in pipelines across the industry. The distribution of these products across the molecular target superfamilies and families highlighted that they predominantly align with the proportional distribution observed across the pain pipeline, with G-protein-coupled receptors and enzymes inhibitors constituting the two major categories. However, an array of novel molecular targets within those groups has been identified, which do not present in any pipeline or marketed products across the industry. A significant degree of innovation has also been identified in other molecular target categories. Active Deals Landscape with Numerous Investment Opportunities The pain deals landscape has been highly active over the past eight years, with 261 licensing deals and 112 co-development deals. However, despite high levels of investment activity, deals for first-in-class products have been relatively rare. To Get More Details Enquire @ http://www.bigmarketresearch.com/report-enquiry/176587

6. Scope • The report covers and includes: • A brief introduction to pain, including the different subtypes of pain, pathophysiology, and overview of pharmacotherapy and treatment algorithms • The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline • A comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target • Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets • Assessment of the licensing and co-development deal landscape for pain therapies and benchmarking of deals involving first-in-class versus non-first-in-class-products

7. Table Of Content 1 Table of Contents 2 Executive Summary 3 The Case for Innovation 4 Clinical and Commercial Landscape 5 Assessment of Pipeline Product Innovation 6 Pain Patent Analysis 7 First-in-Class Target and Pipeline Program Evaluation 8 Deals and Strategic Consolidations 9 Appendix

8. FOR MORE DETAILS Visit us at : http://www.bigmarketresearch.com/frontier-pharma-pain-identifying-and-commercializing-first-in-class-innovation-market Stay With Us: 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@bigmarketresearch.com